Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.
Cammà, C., Petta, S., Cabibbo, G., Ruggeri, M., Enea, M., Bruno, R. A., Capursi, V., Gasbarrini, A., Alberti, A., Craxì, A., Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C, <<JOURNAL OF HEPATOLOGY>>, 2013; 59 (4): 658-666. [doi:10.1016/j.jhep.2013.05.019] [http://hdl.handle.net/10807/52235]
Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
Ruggeri, Matteo;Bruno, Rosa Anna;Gasbarrini, Antonio;
2013
Abstract
Randomised controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin, and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of genotype 1 (G1) chronic hepatitis C (CHC) patients with previous relapse (RR), partial response (PAR), and null-response (NR). We assess the cost-effectiveness of TT compared to no therapy in the treatment of patients previously treated with G1 CHC.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
